相关实验视频

Updated: May 5, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

功能化碳纳米管的分子动力学研究,载有多重多克索鲁比,向叶酸受体α

Cuihong Wang¹, Xin Gao¹, Yue Jiang¹

¹School of Science, Tianjin Chengjian University, Tianjin, China.

Journal of molecular graphics & modelling

|February 5, 2025

概括

两种新的叶酸结合碳纳米管药物递送系统显示出癌症治疗的优秀向性和稳定性. 碳氧化版本展示了卓越的性能,为先进的纳米药物设计提供了洞察力.

科学领域:

纳米技术纳米技术
材料科学材料科学材料科学
计算化学计算化学

背景情况:

向药物递送系统 (DDS) 对于提高治疗效率和减少副作用至关重要.
叶酸受体α (FRα) 在各种癌细胞中过度表达,使其成为药物输送的有希望的标.
碳纳米管 (CNTs) 为药物加载和有针对性的输送提供了一个多功能平台.

研究的目的:

设计和评估两种新型的叶酸结合碳纳米管DDS,用于FRα向药物输送.
通过分子动力学模拟来评估这些DDS的稳定性和准效率.
为了比较碳氧化CNT基DDS与非碳氧化对应物的性能.

主要方法:

设计了两种新型DDS:FOL-CNT/20DOX和FOL-COOH-CNT/24DOX,使用多克索鲁比辛 (DOX) 和与叶酸 (FOL) 结合的碳纳米管 (CNT).
分子动力学 (MD) 模拟以计算叶酸受体α (FRα) 的向性质.
复杂结构的分析,辐射分布函数,距离,角度,键,二次结构,根平均平方位移和根平均平方波动.

主要成果:

这两种新型DDS都表现出高稳定性和对FRα的有效向.
与FOL-CNT/20DOX相比,FOL-COOH-CNT/24DOX系统表现出优越的定位和稳定性.
对动态性质的详细分析证实了DDS和FRα之间的强有力的相互作用.

结论:

设计的叶酸结合CNT DDS是稳定的,有效地准FRα.
FOL-COOH-CNT/24DOX系统提供了增强的向性和稳定性,表明它有可能改善癌症治疗.
这项研究为开发高效的纳米药物递送系统提供了宝贵的见解,具有可控制的药物负载和特定的FRα向.

关键词:

高密度的DOX是一种高密度的DOX 模拟MD的模拟方法有针对性的纳米药物输送系统.

更多相关视频

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...